Zhaoke Ophthalmology, a Guangzhou based biotech company, specializeds in developing a porfolio of drugs to treat various eye diseases .
Investors 1
| Date | Name | Website |
| - | Panacea Ve... | panaceaven... |
Mentions in press and media 2
| Date | Title | Description |
| 11.05.2022 | Visus Therapeutics, Inc., and Zhaoke Ophthalmology Limited Announce Exclusive Licensing Agreement to Commercialize BRIMOCHOL™ PF and Carbachol PF in Greater China, South Korea and Select Southeast Asi... | Collaboration expands access to long-acting, presbyopia-correcting eye drops for approximately 600 million patients Visus to receive upfront payment of $15 million and up to $115 million in potential regulatory and commercial milestone paym... |
| 29.09.2021 | Zhaoke Ophthalmology's IND Application for Potential First Myopia Drug to Market in China and Globally, NVK-002, Approved for Phase III Clinical Trial by the CDE | Targets broadest patient group – three to 17 years old Two concurrent clinical trials, one leveraging global study to accelerate time to market Phase III clinical trials testing two different doses to tailor for individual patients HONG KON... |